Please find attached herewith letter w.r.t.: Update on Slump Sale

Nectar Lifesciences Ltd. Ref. No.: NLL/CS/2026- 697 July 23, 2026 1. National Stock Exchange of India Limited 2. BSE Limited Listing Department, Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, P J Towers, Dalal Street, Bandra (E), Mumbai 400 051 Mumbai 400 001 Symbol: NECLIFE Scrip Code: 532649 Sub.: Transfer of the Empty Hard Gelatin Capsule business (“Business”) on a ‘slump sale’ basis Ref.: Regulation 30 of Securities and Exchange Board of India (“SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”) Dear Sir/ Madam, This is in continuation of disclosures by Nectar Lifesciences Limited (“Company”) regarding the transfer of Business on a ‘slump sale’ basis vide letter no. NLL/CS/2025- WFH dated December 20, 2025, along with Annexure 1 thereto and letter no. NLL/CS/2026- 675 dated April 28, 2026. In this regard, please be informed that the Company and Capnest Health Care Private Limited (“Purchaser”) have mutually agreed to extend the expected completion date of such slump sale to, on or before December 31, 2026. The other relevant disclosures pertaining to slump sale as required under LODR Regulations, have already been provided as per Annexure no. 1 to aforesaid letter no. NLL/CS/2025- WFH dated December 20, 2025, shall remain the same. This is for your information and record please. Thanking you, Yours faithfully, For Nectar Lifesciences Limited (Sanjaymohan Singh Rawat) Company Secretary & Compliance Officer Corporate Office: Plot No. 110, Industrial Area, Phase 1, Chandigarh 160 002, INDIA Registered Office: Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab- 140 507, INDIA Website: www.neclife.com, E-mail: nectar.info@neclife.com CIN: L21000PB1995PLC016664